Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees

NCT00686582 is registered in ClinicalTrials.gov with Bavarian Nordic as lead sponsor.

NCT NCT00686582
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00686582 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees
Lead sponsor
Bavarian Nordic
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2008
Completion date
June 30, 2009
Enrollment
304 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

smallpox